Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance

Heron Therapeutics IncTrade
Roundhill Magnificent Seven ETFTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Roundhill Magnificent Seven ETF — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $61.47M), while Roundhill Magnificent Seven ETF trades at $67.68. The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXMAGS
Market Cap
$61.47M
Sector
HealthSector/Thematic
52-Week High
$1.49$70.94
52-Week Low
$0.32$55.39
Enterprise Value
$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.

Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.

Roundhill Magnificent Seven ETF

MAGS (Roundhill Magnificent Seven ETF) trades at $67.71, down 1.93% amid broader rotation away from concentrated tech exposure. Technical indicators show bullish moving averages but overbought RSI levels, with key support at $67. Recent news highlights the ETF's 181% gain since launch but notes underperformance versus the S&P 500 this year as AI spending pressures tech balance sheets.

The ETF faces headwinds from compressed hyperscaler valuations and declining payout ratios, though AI revenue growth potential remains. Risks include concentration in seven mega-caps and market broadening away from tech leadership. Analyst sentiment is mixed, balancing long-term AI themes against near-term valuation concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Roundhill Magnificent Seven ETF

MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.

Read more on MAGS